Discontinuation of Preventive Medicines in Older People with Limited Life Expectancy: A Systematic Review

Drugs and Aging

Volumn 34, Issue 10, 2017, Pages 767-776

  Narayan, Sujita W ^a   Nishtala, Prasad S ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AGED; AGING; CLINICAL OUTCOME; DEMENTIA; DRUG WITHDRAWAL; HUMAN; LIFE EXPECTANCY; MALIGNANT NEOPLASM; PALLIATIVE THERAPY; PRESCRIPTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TERMINAL DISEASE; TREATMENT WITHDRAWAL; NEOPLASM; PATIENT CARE; PREVENTIVE HEALTH SERVICE; PROCEDURES; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CONTINUITY OF PATIENT CARE; DEMENTIA; HUMANS; LIFE EXPECTANCY; NEOPLASMS; PALLIATIVE CARE; PREVENTIVE HEALTH SERVICES;

EID: 85028746727     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-017-0487-1     Document Type: Review

References (37)

1. Narayan SW, Tordoff JM, Nishtala PS. Temporal trends in the utilisation of preventive medicines by older people: a 9-year population-based study. Arch Gerontol Geriatr. 2016;62:103–11.
2. McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The Burden of polypharmacy in patients near the end of life. J Pain Symptom Manage. 2016;51(2):178–83.e2.
3. Nishtala PS, Narayan SW, Wang T, Hilmer SN. Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf. 2014;23(7):753–8.
4. Narayan SW, Nishtala PS. Associations of potentially inappropriate medicine use with fall-related hospitalisations and primary care visits in older New Zealanders: a population-level study using the updated 2012 Beers Criteria. Drugs Real World Outcomes. 2015;2(2):137–41.
5. Todd A, Husband A, Andrew I, et al. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care. 2017;7(2):113–21.
6. Narayan SW, Nishtala PS. Decade-long temporal trends in the utilization of preventive medicines by centenarians. J Clin Pharm Ther. 2017;42(2):165–9. doi:10.1111/jcpt.12487 (Epub 2016 Dec 10).
7. Kakar P. Preventive medicine in the older patient: a United Kingdom perspective. Int J Prev Med. 2012;3(6):379–85.
8. Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.
9. Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56(10):1946–52.
10. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27(6):435–49.
11. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.
12. Bayliss EA, Bronsert MR, Reifler LM, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.
13. Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.
14. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. Int J Clin Pract. 2016;70(3):261–76.
15. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.
16. Stevenson J, Abernethy AP, Miller C, Currow DC. Managing comorbidities in patients at the end of life. BMJ. 2004;329(7471):909–12.
17. Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.
18. Todd A, Nazar H, Pearson S, et al. Inappropriate prescribing in patients accessing specialist palliative day care services. Int J Clin Pharm. 2014;36(3):535–43.
19. The New Zealand Formulary. http://nzformulary.org/. Accessed 22 July 2016.
20. The Cochrane Collaboration’s tool for assessing risk of bias. London: Cochrane Collaboration. http://handbook.cochrane.org/chapter_8/8_5_the_cochrane_collaborations_tool_for_assessing_risk_of_bias.htm. Accessed 24 Mar 2017.
21. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 24 Mar 2017.
22. STROBE Statement. https://www.strobe-statement.org/index.php?id=strobe-home. Accessed 24 Mar 2017.
23. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.
24. Tjia J, Cutrona SL, Peterson D, et al. Statin discontinuation in nursing home residents with advanced dementia. J Am Geriatr Soc. 2014;62(11):2095–101.
25. Bertozzo G, Zoppellaro G, Granziera S, et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. J Thromb Haemost. 2016;14(11):2124–31.
26. Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2(3):1–6.
27. Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281–5.
28. Nishtala PS, Gnjidic D, Chyou T, Hilmer SN. Discontinuation of statins in a population of older New Zealanders with limited life expectancy. Intern Med J. 2016;46(4):493–6.
29. Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med. 2008;11(5):685–93.
30. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55(4):590–5.
31. Holmes HM, Min LC, Yee M, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655–66.
32. Holmes HM, Todd A. Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med. 2015;175(5):701–2.
33. Poudel A, Yates P, Rowett D, Nissen LM. Use of preventive medication in patients with limited life expectancy: a systematic review. J Pain Symptom Manage. 2017;53(6):1097–1110.e1. doi: 10.1016/j.jpainsymman.2016.12.350 (Epub 2017 Feb 9).
34. Todd A, Husband A, Andrew I, et al. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care. 2017;7(2):113–21. doi:10.1136/bmjspcare-2015-000941 (Epub 2016 Jan 5).
35. Lee SJ, Leipzig RM, Walter LC. Incorporating lag time to benefit into prevention decisions for older adults. JAMA. 2013;310(24):2609–10.
36. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.
37. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55(Suppl 2):S373–82.